In the News

Driving CAR-T Manufacture Optimization through Technology Innovation

Cell & Gene Therapy Insights Latest advances in CAR-T cell manufacture & clinical developments PHILIP H COELHO, Founder and Chief Technology Officer (CTO) of ThermoGenesis Corp., the device Division of Cesca Therapeutics (is an engineer/inventor, educated at the University of California, Davis, where he specialized in thermodynamics and machine design. He has been awarded more … Continued

Cut price Kymriah? ThermoGenesis thinks so with automated CAR-T tech

In August​, Novartis made history when its product Kymriah (tisagenlecleucel) became the first chimeric antigen receptor (CAR) T-cell therapy to win US approval. The product is made by collecting a patient’s cells through apheresis at a specialised clinic before shipping them to a manufacturing site where they are modified, expanded and tested. These are then … Continued

With New Patent, Cesca Eyes Faster, Less Costly CAR-T Cell Production

Chimeric antigen receptor T-cell receptor (CAR-T) and CAR-modified natural killer (CAR-NK) therapeutics can be produced faster and at less cost, Cesca Therapeutics says, through the cellular processing technology covered by a recently awarded patent. Cesca said Friday, July 28, 2017 that U.S. Patent No. 9,695,394, titled “Cell Separation Devices, Systems, and Methods,” has been awarded … Continued

© 2019 ThermoGenesis Corp.
How may we help?